Carcinoma Clinical Trials in Nanjing, Jiangsu
67 recruitingNanjing, Jiangsu, China
Showing 1–20 of 67 trials
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled200 locationsNCT06997497
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401
Recruiting
Phase 2
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital22 enrolled1 locationNCT07435454
Recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Renal Cell CarcinomaCarcinomaKidney Cancer+2 more
Jinling Hospital, China450 enrolled1 locationNCT05917106
Recruiting
Phase 2
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Bladder CancerNeuroendocrine Carcinoma of the Bladder
RenJi Hospital22 enrolled5 locationsNCT06091124
Recruiting
Phase 2
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University460 enrolled1 locationNCT07263386
Recruiting
Phase 2
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China30 enrolled1 locationNCT07175480
Recruiting
Phase 2
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Jinling Hospital, China35 enrolled1 locationNCT06255223
Recruiting
Phase 3
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University422 enrolled5 locationsNCT06492460
Recruiting
Phase 2
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma of the Renal Pelvis and Ureter+1 more
Mabwell (Shanghai) Bioscience Co., Ltd.60 enrolled2 locationsNCT06823427
Recruiting
Phase 4
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Triple-Negative Breast CancerCarcinoma BreastInvasive Ductal Carcinoma, Breast
Fudan University1,072 enrolled34 locationsNCT04790305
Recruiting
Phase 2
NALIRIFOX as Induction Therapy in LAPC
Pancreatic Ductal Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University20 enrolled1 locationNCT06467565
Recruiting
Phase 2
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma Metastatic
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School177 enrolled1 locationNCT06051851
Recruiting
Phase 2
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
Non-clear Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School30 enrolled2 locationsNCT05768464
Recruiting
Not Applicable
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Esophageal Squamous Cell CarcinomaChemoradiotherapySurvival
Fudan University320 enrolled3 locationsNCT04519905